• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Abpro Holdings Inc filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    10/22/25 5:00:27 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABP alert in real time by email
    false --12-31 0001893219 0001893219 2025-10-16 2025-10-16 0001893219 ABPWW:SharesOfCommonStockParValue0.0001PerShareMember 2025-10-16 2025-10-16 0001893219 ABPWW:WarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member 2025-10-16 2025-10-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): October 16, 2025

     

    Abpro Holdings, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41224   87-1013956
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (I.R.S. Employer
    Identification No.)

     

    100 Summit Drive

    Burlington, MA

      01803
    (Address of principal executive offices)   (Zip Code)

     

    1-800-396-5890

    (Registrant’s telephone number, including area code)

     

    N/A 

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class   Trading Symbol(s)   Name of Each Exchange on Which Registered
    Shares of Common Stock, par value $0.0001 per share   ABP   The Nasdaq Stock Market LLC
    Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50   ABPWW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

     

    On October 16, 2025, Abpro Holdings, Inc. (the “Company”) filed with the Delaware Secretary of State a Certificate of Amendment to the Certificate of Incorporation of the Company (the “Certificate of Amendment”), which will become effective at 5:01 p.m. on October 31, 2025 (the “Effective Time”), to effect a one-for-thirty (1:30) reverse stock split (the “Reverse Stock Split”), of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). The Reverse Stock Split was approved by the Company’s stockholders at the 2025 annual meeting of the stockholders on October 10, 2025.

     

    As a result of the Reverse Stock Split, every 30 shares of issued and outstanding Common Stock will be automatically combined into one (1) issued and outstanding share of Common Stock, without any change in the par value per share. No fractional shares will be issued as a result of the Reverse Stock Split. Instead, stockholders who otherwise would have been entitled to receive fractional shares because they held a number of shares not evenly divisible by the Reverse Stock Split ratio will be entitled to receive an additional fraction of a share of Common Stock to round up to the next whole share.

     

    Following the Reverse Stock Split, the number of shares of Common Stock outstanding will be proportionally reduced from 81,150,000 shares to approximately 2,705,000 shares. The shares of Common Stock underlying the Company’s outstanding stock options and warrants will be similarly adjusted along with corresponding adjustments to their exercise prices.

     

    The Company’s transfer agent, Continental Stock Transfer & Trust Company, is the exchange agent for the Reverse Stock Split and will correspond with stockholders of record regarding the Reverse Stock Split. Stockholders owning shares via a broker or other nominee will have their positions automatically adjusted to reflect the Reverse Stock Split.

     

    The Common Stock will begin trading on a reverse stock split-adjusted basis upon market open on November 3, 2025. The ticker symbol for the Common Stock will remain “ABP.” The new CUSIP number for the Common Stock following the Reverse Stock Split will be 000847202.

     

    The forgoing description of the Certificate of Amendment does not purport to be complete and is subject to, and is qualified in its entirety by reference to, the full text of the Certificate of Amendment, which is attached as Exhibit 3.1 to this Current Report on Form 8-K, and is incorporated herein by reference.

     

    Item 9.01 Financial Statements and Exhibits

     

    (d) Exhibits

     

    Exhibit
    No.
      Description
    3.1   Certificate of Amendment to Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on October 16, 2025.
    104   Cover Page Interactive Data File (embedded within the inline XBRL document)

     

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      ABPRO HOLDINGS, INC.
         
      By: /s/ Miles Suk
      Name:  Miles Suk
      Title: Chief Executive Officer
         
    Dated: October 22, 2025    

     

     

    2

     

     

    Get the next $ABP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ABP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Lee Soo Young

    4 - Abpro Holdings, Inc. (0001893219) (Issuer)

    8/7/25 9:08:24 AM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman Suk Jin Wook (Miles) bought $20,170 worth of shares (72,035 units at $0.28), increasing direct ownership by 11% to 718,512 units (SEC Form 4)

    4 - Abpro Holdings, Inc. (0001893219) (Issuer)

    8/4/25 5:22:41 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Eisenberg Anthony D.

    4 - Abpro Holdings, Inc. (0001893219) (Issuer)

    7/29/25 9:23:12 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABP
    SEC Filings

    View All

    SEC Form S-1 filed by Abpro Holdings Inc

    S-1 - Abpro Holdings, Inc. (0001893219) (Filer)

    11/7/25 7:41:41 AM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Abpro Holdings Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K/A - Abpro Holdings, Inc. (0001893219) (Filer)

    11/4/25 10:45:30 AM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abpro Holdings Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Abpro Holdings, Inc. (0001893219) (Filer)

    11/4/25 7:00:41 AM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager

    CT-P72/ABP-102 poster selected as one of the Top 150 abstracts out of more than 1,300 submissions at SITC 2025 CT-P72/ABP-102 demonstrates potent and selective anti-tumor activity in HER2-high models, including Enhertu-resistant tumorsDual-affinity engineering reduces on-target, off-tumor activity and supports a favorable preclinical safety profileData supports advancement toward clinical development in HER2-positive cancers BURLINGTON, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Abpro Corporation (NASDAQ:ABP) ("Abpro") and Celltrion, Inc. ("Celltrion") today announced that they will present new preclinical data for CT-P72/ABP-102, a tetravalent bispecific antibody targeting HER2 and CD3, a

    11/4/25 9:15:00 AM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025

    Achieved ~60% reduction in operating costs through a focused cost optimization plan DiversImmune® platform positioned to unlock additional pipeline value Reverse stock split supports Nasdaq compliance and positions company for next phase of growth BURLINGTON, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro" or the "Company"), a biotechnology company advancing next-generation antibody therapies, today announced that its previously approved 1-for-30 reverse stock split (the "Reverse Stock Split") of its common stock became effective at 5:01 p.m. Eastern Time on October 31, 2025. The Company's common stock will begin trading on a split-adjusted basis at t

    11/3/25 7:00:00 AM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sitryx appoints Adam Mostafa as Chief Financial Officer

    Sitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK and Boston, MA – 8 September 2025 – Sitryx Therapeutics ("the Company"), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announces the appointment of Adam Mostafa as Chief Financial Officer (CFO), effective today. With over 25 years of experience, Adam is a seasoned biotech executive and financial leader. He joins Sitryx with a distinguished background spanning across biotech and healthcare financial

    9/8/25 7:00:00 AM ET
    $ABP
    $CPIX
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ABP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and Chairman Suk Jin Wook (Miles) bought $20,170 worth of shares (72,035 units at $0.28), increasing direct ownership by 11% to 718,512 units (SEC Form 4)

    4 - Abpro Holdings, Inc. (0001893219) (Issuer)

    8/4/25 5:22:41 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman Suk Jin Wook (Miles) bought $4,212 worth of shares (16,200 units at $0.26), increasing direct ownership by 12% to 146,477 units (SEC Form 4)

    4 - Abpro Holdings, Inc. (0001893219) (Issuer)

    5/19/25 8:37:52 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman Suk Jin Wook (Miles) bought $1,081 worth of shares (4,325 units at $0.25), increasing direct ownership by 3% to 130,277 units (SEC Form 4)

    4 - Abpro Holdings, Inc. (0001893219) (Issuer)

    5/1/25 4:21:30 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABP
    Leadership Updates

    Live Leadership Updates

    View All

    Sitryx appoints Adam Mostafa as Chief Financial Officer

    Sitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK and Boston, MA – 8 September 2025 – Sitryx Therapeutics ("the Company"), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announces the appointment of Adam Mostafa as Chief Financial Officer (CFO), effective today. With over 25 years of experience, Adam is a seasoned biotech executive and financial leader. He joins Sitryx with a distinguished background spanning across biotech and healthcare financial

    9/8/25 7:00:00 AM ET
    $ABP
    $CPIX
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Abpro Statement on the Departure of Former CEO Ian Chan

    WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases announced today the departure of Chief Executive Officer Ian Chan. Commenting on the leadership change, Abpro Board Chairman and CEO Miles Suk, said, "As disclosed in our regulatory filing on Friday, the Board has decided to part ways with Ian Chan. I want to thank Ian for his service and wish him well. This leadership transition, however, does not affect our stability or direction. Instead, it marks the first step toward a stronger, more promising future. We remain fully co

    3/10/25 6:34:55 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care